The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Momelotinib vs ruxolitinib in patients with MF by baseline hemoglobin levels: Exploratory post hoc analysis from SIMPLIFY-1
|
The phase III SIMPLIFY-1 trial (NCT01969838) evaluated momelotinib vs ruxolitinib in Janus kinase inhibitor (JAKi)-naïve patients with myelofibrosis (MF).1 The MPN Hub previously reported long-term outcomes and updated results from this trial. An exploratory post hoc analysis from this trial assessed the benefits of momelotinib in subgroups defined by baseline hemoglobin levels (moderate/severe anemia, <10 g/dL; mild anemia, ≥10 to <12 g/dL; nonanemic, ≥12 g/dL).1 Results from this analysis were published in Leukemia & Lymphoma by Gupta et al.1 |
| Key learnings1 |
| Momelotinib demonstrated an advantage in transfusion independence rates at Week 24 over ruxolitinib in anemic patients, particularly in the mildly anemic subgroup (moderate/severe anemia, 46.5% vs 26.6%; mild anemia, 80.8% vs 50.7%), while the benefit was less clear in nonanemic patients (78.6% vs 86.8%). |
| The safety profile of momelotinib remained consistent across the subgroups, with fewer key hematologic treatment-emergent adverse events, including anemia and thrombocytopenia, compared with ruxolitinib, potentially allowing for full-dose administration in more patients. |
| Momelotinib provided similar splenic response rates at Week 24 to ruxolitinib across all subgroups, but with the added benefit of better anemia management, highlighting its comprehensive efficacy in treating patients with MF. |
| These findings are consistent with the overall patient population of the SIMPLIFY-1 trial and suggest that momelotinib is a viable treatment option for patients with MF regardless of baseline hemoglobin levels, as it offers a balanced approach to managing anemia without compromising on spleen or symptom benefits. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content